Scrip Symbol
SUVEN
Event Details
Suven Life Sciences Limited announced it will present seven scientific posters highlighting its central nervous system (CNS) drug discovery and development pipeline at Neuroscience 2026, the annual meeting of the Society for Neuroscience (SfN). The conference will be held in Washington, DC, USA during November 14-18, 2026.
Presentation Schedule and Details
The seven scientific posters to be presented are:
- SUVN-M8036: A multimodal receptor antagonist exhibiting antipsychotic and anti-aggressive-like effects in animal models. Presentation scheduled for November 14, 2026, 1:00 PM-5:00 PM, Poster N7.
- SUVN-I6107 (Tenaclidine): Safety, tolerability, and pharmacokinetics of a pure M1 positive allosteric modulator from a first-in-human study in healthy subjects. Presentation scheduled for November 14, 2026, 1:00 PM-5:00 PM, Poster JJ10.
- SUVN-L1101142: A novel muscarinic M4 positive allosteric modulator for treating Alzheimer's Disease and schizophrenia. Presentation scheduled for November 14, 2026, 1:00 PM-5:00 PM, Poster JJ11.
- Samelisant: Efficacy and safety of an H3 receptor inverse agonist for treating narcolepsy with or without cataplexy from a Phase 3 study. Presentation scheduled for November 16, 2026, 1:00 PM-5:00 PM, Poster EE18.
- SUVN-N9503012: Efficacy of a selective 5-HT1A receptor partial agonist intended for treating L-Dopa-Induced Dyskinesia. Presentation scheduled for November 17, 2026, 8:00 AM-12:00 PM, Poster W18.
- Ropanicant (SUVN-911): A Phase 2b randomized, double-blind, placebo-controlled study evaluating efficacy and safety in patients with Major Depressive Disorder. Presentation scheduled for November 17, 2026, 8:00 AM-12:00 PM, Poster II27.
- Masupirdine (SUVN-502): Baseline characteristics from a Phase-3 study in Alzheimer's Dementia with agitation. Presentation scheduled for November 17, 2026, 1:00 PM-5:00 PM, Poster V22.
Therapeutic Areas Covered
The presentations span multiple CNS therapeutic areas including Alzheimer's Disease, Agitation, Schizophrenia, Narcolepsy, Sleep Disorders, Major Depressive Disorder, and Parkinson's Disease.
Management Commentary
Mr. Venkat Jasti, Chairman and Managing Director, stated that the participation reflects the breadth and progress of Suven's CNS R&D pipeline with a diverse portfolio across multiple therapeutic areas. The company has candidates in Phase-3 and Phase-2 clinical development alongside preclinical programs progressing toward clinical evaluation.
Ramakrishna Nirogi, President and Chief Scientific Officer, highlighted that the research encompasses multiple pharmacological mechanisms including muscarinic M1 and M4 modulation, histamine H3 receptor inverse agonism, serotonin receptor modulation, and nicotinic receptor antagonism. The presentations include findings from clinical studies of advanced candidates and preclinical research supporting next-generation pipeline development.
Conference Engagement
SfN attendees are invited to visit Suven's Exhibit Booth #423, where senior representatives from Suven Life Sciences, India and Suven Neurosciences, USA will be available throughout the conference to discuss the clinical-stage neuroscience pipeline, development programs, future strategy, and collaboration opportunities.
Company Pipeline Overview (as disclosed)
Suven has five clinical-stage assets:
- Masupirdine (SUVN-502): Global Phase-3 study for agitation in Alzheimer's dementia (enrollment completed)
- Samelisant (SUVN-G3031): Phase-3 AWAKE study for excessive daytime sleepiness in narcolepsy initiated; Phase-2 study for cataplexy in planning
- Ropanicant (SUVN-911): Phase-2b study for Major Depressive Disorder completed; Phase-3 study in planning
- Usmarapride (SUVN-D4010): Phase-2 study for cognitive disorders in planning
- Tenaclidine (SUVN-I6107): Phase-1 study completed; long-term toxicity studies in progress
The company also has seven projects in research pipeline across multiple indications and owns all intellectual property rights for its assets in all major world markets.
Financial Impact
Financial impact not quantified in the disclosure.